SUTRO BIOPHARMA, INC. (STRO) Payables and obligations
- Other obligations · latest quarter (USD): Value (m); Formula and calculation Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30..
- Payables · latest quarter (USD): Value $3.36M; Formula and calculation Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30..
- Deferred revenue · latest quarter (USD): Value $6.46M; Formula and calculation Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30..
- Other obligations · due within 1 year (USD): Value $2.73M; Formula and calculation Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30..
Payables and obligations
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Other obligations · latest quarter (USD) | (m) | Total liabilities − borrowing debt − payables − total deferred revenue. Includes accruals, taxes, leases and other obligations; excludes the separately shown balances. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Payables · latest quarter (USD) | $3.36M | Amounts owed to suppliers, reported accounts payable. Period ending 2026-06-30. Reported amount: $3.36M |
| Deferred revenue · latest quarter (USD) | $6.46M | Current and noncurrent customer contract obligations; payments received before revenue is earned. Period ending 2026-06-30. $6.46M + $0.00 ≈ $6.46M |
| Other obligations · due within 1 year (USD) | $2.73M | Reported other current liabilities. Excludes separately reported debt, payables and current deferred revenue. The saved current-quarter facts do not separately disclose taxes, payroll, leases or accruals. Period ending 2026-06-30. Reported amount: $2.73M |
| Other obligations · due after 1 year (USD) | $1.69M | Reported other noncurrent liabilities minus the noncurrent deferred revenue they include (total customer contract obligations − current portion); a separately reported noncurrent deferred revenue line is not deducted. The saved current-quarter facts do not separately disclose taxes, leases or other accruals. Period ending 2026-06-30. $1.69M − $0.00 ≈ $1.69M |
Calculation inputs
Other obligations breakdown
- Other obligations · due within 1 year (USD)
- $2.73M
- Other obligations · due after 1 year (USD)
- $1.69M
Bonds and commercial paper are already included in Total debt. Other obligations include taxes, accrued expenses and operating/finance leases. Category amounts below are the issuer’s own tagged balances at the same quarter end; untagged categories are not shown.
| Category | Quarter ending 2026-06-30 |
|---|---|
| Operating lease obligations | $10.78M |
These categories are parts of the combined obligations, not additional deductions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Other obligations | Payables | Deferred revenue | Short-term obligations | Long-term obligations | Total reported obligations (USD) | Borrowing debt (USD) | Deferred revenue due within one year (USD) | Deferred revenue due after one year (USD) | Reported other noncurrent obligations (USD) | Deferred revenue included in other noncurrent obligations (USD) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $3.36M | $6.46M | $2.73M | $1.69M | $297.78M | (m) | $6.46M | $0.00 | $1.69M | $0.00 |
| 2026-03-31 | (m) | $5.49M | $10.63M | $3.03M | $1.69M | $308.88M | (m) | $9.40M | $1.23M | $1.69M | $0.00 |
| 2025-12-31 | (m) | $7.57M | $12.59M | $2.91M | $1.69M | $306.28M | (m) | $10.56M | $2.03M | $1.69M | $0.00 |
| 2025-09-30 | (m) | $7.03M | $12.73M | $15.79M | $1.69M | $296.93M | (m) | $8.98M | $3.76M | $1.69M | $0.00 |
| 2025-06-30 | (m) | $4.31M | $18.87M | $17.83M | $1.69M | $294.47M | (m) | $11.96M | $6.91M | $1.69M | $0.00 |
| 2025-03-31 | (m) | $8.18M | $77.54M | $14.17M | $1.69M | $347.24M | (m) | $68.98M | $8.57M | $1.69M | $0.00 |
| 2024-12-31 | (m) | $10.47M | $82.32M | $4.01M | $1.69M | $342.61M | (m) | $69.78M | $12.54M | $1.69M | $0.00 |
| 2024-09-30 | (m) | $6.22M | $90.56M | $3.46M | $1.69M | $340.61M | (m) | $72.56M | $18.00M | $1.69M | $0.00 |
| 2024-06-30 | (m) | $6.09M | $95.65M | $3.58M | $1.69M | $336.87M | (m) | $73.96M | $21.69M | $1.69M | $0.00 |
| 2024-03-31 | (m) | $7.51M | $66.81M | $3.41M | $1.69M | $305.38M | (m) | $20.50M | $46.31M | $1.69M | $0.00 |
| 2023-12-31 | (m) | $9.44M | $74.05M | $3.90M | $1.69M | $321.09M | (m) | $20.67M | $53.38M | $1.69M | $0.00 |
| 2023-09-30 | (m) | $5.53M | $102.14M | $3.04M | (m) | $319.39M | (m) | $23.98M | $78.15M | (m) | $0.00 |
| 2023-06-30 | (m) | $3.86M | $97.92M | $7.33M | (m) | $310.18M | (m) | $18.04M | $79.88M | (m) | $0.00 |
| 2023-03-31 | (m) | $5.06M | $102.23M | $2.19M | (m) | $172.60M | (m) | $17.19M | $85.05M | (m) | $0.00 |
| 2022-12-31 | (m) | $4.80M | $106.64M | $3.08M | $119.00K | $189.90M | (m) | $16.76M | $89.89M | $119.00K | $0.00 |
| 2022-09-30 | (m) | $12.44M | $90.65M | $4.41M | $133.00K | $170.97M | (m) | $15.92M | $74.73M | $133.00K | $0.00 |
| 2022-06-30 | (m) | $12.57M | $96.49M | $4.15M | $142.00K | $176.56M | (m) | $6.49M | $90.00M | $142.00K | $0.00 |
| 2022-03-31 | (m) | $10.71M | (m) | $2.79M | (m) | $83.30M | (m) | $6.28M | (m) | $147.00K | (m) |
| 2021-12-31 | (m) | $11.33M | (m) | $3.08M | (m) | $88.84M | (m) | $5.50M | (m) | $146.00K | (m) |
| 2021-09-30 | (m) | $11.17M | $7.95M | $296.00K | $1.50M | $87.89M | (m) | $7.80M | $145.00K | $1.50M | $0.00 |
| 2021-06-30 | (m) | $7.64M | $8.32M | $720.00K | $844.00K | $52.29M | (m) | $8.13M | $193.00K | $844.00K | $0.00 |
| 2021-03-31 | (m) | $5.89M | $12.91M | $185.00K | $638.00K | $51.19M | (m) | $12.09M | $822.00K | $638.00K | $0.00 |
| 2020-12-31 | (m) | $5.54M | $20.70M | $627.00K | $481.00K | $62.06M | (m) | $14.60M | $6.10M | $481.00K | $0.00 |
| 2020-09-30 | (m) | $4.88M | $24.07M | $3.44M | $151.00K | $63.12M | (m) | $15.70M | $8.37M | $151.00K | $0.00 |
| 2020-06-30 | (m) | $4.90M | $34.06M | $2.54M | $148.00K | $70.78M | (m) | $23.50M | $10.56M | $148.00K | $0.00 |
| 2020-03-31 | (m) | $5.84M | $37.99M | $352.00K | $141.00K | $71.79M | (m) | $22.87M | $15.11M | $141.00K | $0.00 |
| 2019-12-31 | (m) | $5.58M | $35.66M | $901.00K | $134.00K | $58.58M | (m) | $19.46M | $16.20M | $134.00K | $0.00 |
| 2019-09-30 | (m) | $4.55M | $40.10M | $589.00K | $129.00K | $61.77M | (m) | $20.25M | $19.85M | $129.00K | $0.00 |
| 2019-06-30 | (m) | $4.52M | $46.96M | $832.00K | $125.00K | $69.26M | (m) | $21.38M | $25.58M | $125.00K | $0.00 |
| 2019-03-31 | (m) | $3.40M | $50.54M | $443.00K | $121.00K | $71.74M | (m) | $19.02M | $31.52M | $121.00K | $0.00 |
| 2018-12-31 | (m) | $3.06M | $66.17M | $847.00K | $102.00K | $91.60M | (m) | $21.57M | $44.60M | $102.00K | $0.00 |
| 2018-09-30 | (m) | $4.59M | $73.03M | $815.00K | $664.00K | $99.21M | (m) | $24.23M | $48.80M | $664.00K | $0.00 |
| 2017-12-31 | (m) | $2.90M | $23.87M | $72.00K | $14.00K | $47.27M | (m) | $10.71M | $13.16M | $14.00K | $0.00 |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |